Vaxcyte, Inc. PCVX Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Vaxcyte, Inc. (PCVX) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $340.63M in Q1 2026.
- How has Vaxcyte, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- Vaxcyte, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 22.3% year-over-year, from $438.49M to $340.63M.
- What is the long-term trend for Vaxcyte, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 108.6% compound annual growth rate (CAGR), from $168.69M to $1.53B.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.